## **ICMJE DISCLOSURE FORM**

Date:		7/26/2023	7/26/2023		
Your Name:		Robert Damstra	Robert Damstra		
Manuscript Title:		Wekedeleninfecties	Wekedeleninfecties		
Manuscript Number (if known):		known):			
cont affect indice The epid that	eent of your manuscr cted by the content of cate a bias. If you are author's relationship emiology of hyperte medication is not m	ript. "Related" means any relation with for-profit or not the manuscript. Disclosure represents a commitme in doubt about whether to list a relationship/activity os/activities/interests should be defined broadly. For onsion, you should declare all relationships with manufentioned in the manuscript.  all support for the work reported in this manuscript we	rt for the work reported in this manuscript without time limit. For all other items, the time		
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial planning	of the work		
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	None	Click the tab key to add additional rows.		
		Time frame: past 36 month	s		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None			
3	Royalties or licenses	None     Non			

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	UIP congress Miami in September 2023. I am member of the program comity and chair / moderator / /speaker	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Member LE&LR Chair PPL-ERN rare diseases Chair lymphedema working group NL	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None			
Please place an "X" next to the following statement to indicate your agreement:    I certify that I have answered every question and have not altered the wording of any of the questions on this form.					